Shares of Akero Therapeutics, Inc. (NASDAQ:AKRO – Get Free Report) have earned an average recommendation of “Moderate Buy” from the nine ratings firms that are presently covering the stock, MarketBeat Ratings reports. One equities research analyst has rated the stock with a hold rating and eight have assigned a buy rating to the company. The average 12 month price objective among analysts that have issued ratings on the stock in the last year is $41.13.
A number of research firms recently weighed in on AKRO. Wolfe Research assumed coverage on shares of Akero Therapeutics in a report on Tuesday, June 11th. They issued an “outperform” rating on the stock. Cantor Fitzgerald reissued an “overweight” rating on shares of Akero Therapeutics in a research note on Thursday, June 20th. Finally, HC Wainwright reaffirmed a “buy” rating and set a $50.00 target price on shares of Akero Therapeutics in a research report on Tuesday, September 17th.
Get Our Latest Stock Report on Akero Therapeutics
Insider Activity
Institutional Trading of Akero Therapeutics
Several hedge funds and other institutional investors have recently modified their holdings of the business. Janus Henderson Group PLC boosted its holdings in Akero Therapeutics by 42.2% in the 1st quarter. Janus Henderson Group PLC now owns 6,121,970 shares of the company’s stock worth $154,589,000 after buying an additional 1,815,569 shares during the period. Price T Rowe Associates Inc. MD lifted its holdings in shares of Akero Therapeutics by 10.5% in the first quarter. Price T Rowe Associates Inc. MD now owns 4,060,479 shares of the company’s stock worth $102,569,000 after buying an additional 384,555 shares in the last quarter. Vanguard Group Inc. boosted its position in shares of Akero Therapeutics by 19.0% in the first quarter. Vanguard Group Inc. now owns 3,669,923 shares of the company’s stock valued at $92,702,000 after acquiring an additional 584,875 shares during the period. RTW Investments LP bought a new stake in Akero Therapeutics during the 4th quarter worth approximately $83,891,000. Finally, Wellington Management Group LLP increased its holdings in Akero Therapeutics by 247.7% during the 4th quarter. Wellington Management Group LLP now owns 2,881,989 shares of the company’s stock worth $67,294,000 after acquiring an additional 2,053,028 shares during the period.
Akero Therapeutics Stock Up 1.0 %
Shares of NASDAQ:AKRO opened at $28.37 on Tuesday. The company has a debt-to-equity ratio of 0.04, a quick ratio of 24.89 and a current ratio of 24.89. Akero Therapeutics has a 52-week low of $11.25 and a 52-week high of $51.24. The business’s 50 day simple moving average is $26.35 and its two-hundred day simple moving average is $23.86. The firm has a market cap of $1.96 billion, a P/E ratio of -8.87 and a beta of -0.26.
Akero Therapeutics (NASDAQ:AKRO – Get Free Report) last posted its quarterly earnings results on Friday, August 9th. The company reported ($0.81) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.90) by $0.09. As a group, research analysts forecast that Akero Therapeutics will post -3.64 EPS for the current fiscal year.
Akero Therapeutics Company Profile
Akero Therapeutics, Inc, together with its subsidiary, engages in the development of treatments for patients with serious metabolic diseases in the United States. The company's lead product candidate is efruxifermin (EFX), which is in Phase 3 clinical trials that protects against cellular stress and regulates the metabolism of lipids, carbohydrates, and proteins throughout the body for the treatment of biopsy-confirmed metabolic dysfunction-associated steatohepatitis (MASH) patients.
See Also
- Five stocks we like better than Akero Therapeutics
- How to Plot Fibonacci Price Inflection Levels
- The Average 401k Balance by Age Explained
- Most Volatile Stocks, What Investors Need to Know
- 3 Uranium Stocks To Gain as Microsoft Goes Nuclear to Power AI
- What is the Dogs of the Dow Strategy? Overview and Examples
- Biotech Boom Ahead? Key Stocks and ETFs to Watch Now
Receive News & Ratings for Akero Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Akero Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.